Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

arGen-X Raises $37 Million To Advance Its Human Antibodies Into The Clinic

This article was originally published in The Pink Sheet Daily

Executive Summary

European biotech arGEN-X adds U.S VC firm OrbiMed as an investor as it raises $37 million in a Series B financing.

Advertisement

Related Content

RuiYi Signs On New Partners To Develop Anti-IL6 mAb In China
China First: RuiYi Takes Exclusive License To arGEN-X’s Anti-IL6 Antibody
China First: RuiYi Takes Exclusive License To arGEN-X’s Anti-IL6 Antibody
Creabilis Pulls In Corporate VC With €15M Series B

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel